Barbara Adamo

Research group

Translational genomics and targeted therapies in solid tumours Accredited researcher (R3A)

adamo@clinic.cat 0000-0001-7129-8156

Featured publications

Gene expression profiles of breast cancer metastasis according to organ site

Authors:
Braso-Maristany, Fara; Pare, Laia; Chic, Nuria; Martinez-Saez, Olga; Pascual, Tomas;

(...)

Adamo, Barbara; Moreno, Reinaldo; Vidal, Maria; Munoz, Montserrat; Prat, Aleix.

Reference: Molecular Oncology 2022.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Authors:
Chic, Nuria; Schettini, Francesco; Braso-Maristany, Fara; Sanfeliu, Esther; Adamo, Barbara;

(...)

Munoz, Montserrat; Perou, Charles M; Pascual, Tomas; Bellet, Meritxell; Prat, Aleix.

Reference: Ebiomedicine 2021.
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

Authors:
Pascual, Tomas; Fernandez-Martinez, Aranzazu; Tanioka, Maki; Dieci, M Vittoria; Pernas, Sonia;

(...)

Pare, Laia; Galvan, Patricia; Carey, Lisa A; Perou, CharlesM; Prat, Aleix.

Reference: Clinical Cancer Research 2021.
COVID-19 pandemic impact in newly diagnosed breast cancer patients (BCP) at a third level hospital

Authors:
Sacoto, MCG; Moreno, R; Rodríguez, A; Núñez-Manchón, E; Bargalló, X;

(...)

Mollà, M; González, GO; Gonzalez-Farre, B; Font, JF; Vidal-Sicart, S.

Reference: Annals Of Oncology 2021.
Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)

Authors:
Laguna, JC; Hernandez, AR; Chic, N; Adamo, B; Vidal, M;

(...)

Galván, P; Díez-Guardia, V; Pascual, T; Torres, ES; Gonzalez-Farre, B.

Reference: Annals Of Oncology 2021.
CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data

Authors:
Martínez-Sáez, O; Hernandez, AR; Chic, N; Laguna, JC; Vidal, M;

(...)

Schettini, F; Parrilla, L; Ruano, Y; Torres, ES; Gonzalez-Farre, B.

Reference: Annals Of Oncology 2021.
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Authors:
Martinez-Saez, Olga; Pascual, Tomas; Braso-Maristany, Fara; Chic, Nuria; Gonzalez-Farre, Blanca;

(...)

Salvador, Fernando; Ciruelos, Eva M; Faull, Iris; Odegaard, Justin I; Prat, Aleix.

Reference: Npj Breast Cancer 2021.
Molecular characterization of advanced breast cancer according to site of metastasis

Authors:
Braso-Maristany, Fara; Pare, Laia; Chic, Nuria; Martinez-Saez, Olga; Pascual, Tomas;

(...)

Adamo, Barbara; Moreno, Reinaldo; Vidal, Maria; Munoz, Montserrat; Prat, Aleix.

Reference: Cancer Research 2021.
Solti-1502 aRIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer

Authors:
Oliveira, Mafalda; Pernas, Sonia; Margeli, Mireia; Blanch, Salvador; Adamo, Barbara;

(...)

Prat, Aleix; Pascual, Tomas; Ferrero-Cafiero, Juan M; Villagrasa, Patricia; Manso, Luis.

Reference: Cancer Research 2021.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Authors:
Schettini, Francesco; Pascual, Tomas; Conte, Benedetta; Chic, Nuria; Braso-Maristany, Fara;

(...)

Osborne, C Kent; Pernas, Sonia; Perou, Charles M; Carey, Lisa A; Prat, Aleix.

Reference: Cancer Treatment Reviews 2020.

Featured Projects

Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Principal investigator: Aleix Prat Aparicio

Duration: 15/09/2019 - 14/09/2022
Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer

Principal investigator: Aleix Prat Aparicio

Code: INT_BCN_Catalyst_18

Duration: 01/03/2019 - 28/02/2023
Caracterización de los linfocitos T CD8+PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched

Duration: 01/01/2019 - 01/01/2020
FIS-ISCIII: Análisis de eficacia de inhibidores cDK4/6 en combinación con tratamiento hormonal en base al subtipo intrínseco y marcadores de inmunidad

Duration: 01/01/2018
Convocatòria d'ajuts per donar suport a les activitats dels grups de recerca SGR 2017-2019

Principal investigator: FAya

Duration: 01/01/2017 - 01/01/2019

Barbara Adamo

Research group

Featured publications

Molecular characterization of advanced breast cancer according to site of metastasis

Featured Projects

Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer

Caracterización de los linfocitos T CD8+PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched

FIS-ISCIII: Análisis de eficacia de inhibidores cDK4/6 en combinación con tratamiento hormonal en base al subtipo intrínseco y marcadores de inmunidad

Convocatòria d'ajuts per donar suport a les activitats dels grups de recerca SGR 2017-2019

Subscribe to the Newsletter of Clínic